Business Development

Business Development

Dr Daniel Gray in FACS lab
Our Business Development team is comprised of highly qualified professionals with expertise in biomedical science, biotech and industry research and development, business development, intellectual property management and commercialisation. 

Business Development Office staffWEHI has a strong track record in early capture of intellectual property and translation through commercialisation, translation and entrepreneurship.

We collaborate with some of the most respected names within both the private and public sectors to translate our discovery science and ensure that patients benefit from research conducted at WEHI.


Opportunity identification, partner identification and engagement

Commercialisation and Business Development

We work across the Institute’s research themes to identify innovative discoveries that have the commercial potential to make a positive impact on the community.

In collaboration with our scientists we to determine how best to translate these discoveries through clinical collaborations, partnering with industry or exploring spinoff formation in order to secure the best outcomes for patients

Intellectual property and agreements management

We manage WEHI's intellectual property portfolio and all agreements relating to commercialisation of WEHI's research including material transfer agreements, license agreements, collaboration agreements, and confidentiality agreements.

Our team includes experienced patent managers and legal counsel to provide specialist expertise in these areas.

Education and training

Our researchers have the opportunity to develop skills in technology transfer, business development, commercialisation and entrepreneurship through our Business Development Internship program.

Licensed / Developing Technologies

Our research teams focus on solving complex biological questions and linking laboratory results to clinical outcomes. Through our established partnerships with pharmaceutical or biotech companies we are developing novel compounds that could be effective in treating several types of cancer, immune disorders and infectious diseases.

Start-up companies

The Business Development Office supports the development of start-up companies created based on intellectual property developed within WEHI.


Fast figures
  • The discovery pipeline is fed by more than 300 projects

  • A new patent application is filed every two weeks

  • At least one material transfer agreement (MTA) is executed every working day

  • WEHI’s intellectual property is the subject of more than 100 clinical trials currently being conducted worldwide.

Venetoclax timeline of discovery

Starting with a landmark discovery in 1988, follow the story of how Institute research has driven development of a breakthrough anti-cancer drug.